[1]Laoukili J,Stahl M,Medema RH.FoxM1:at the crossroads of ageing and cancer[J].Biochimica et Biophysica Acta,2007,1775(1):92-102.
[2]Gu C,Yang Y,Sompallae R,et al.FOXM1 is a therapeutic target for high-risk multiple myeloma[J].Leukemia,2016,30(4):873-882.
[3]Pilarsky C,Wenzig M,Specht T,et al.Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data[J].Neoplasia,2004,6(6):744-750.
[4]Halasi M,Gartel AL.FOX(M1) news-it is cancer[J].Molecular Cancer Therapeutics,2013,12(3):245-254.
[5]Hanahan D,Weinberg RA.Hallmarks of cancer:the next generation[J].Cell,2011,144(5):646-674.
[6]Bhat UG,Jagadeeswaran R,Halasi M,et al.Nucleophosmin interacts with FOXM1 and modulates the level and localization of FOXM1 in human cancer cells[J].J Biol Chem,2011,286(48):41425-41433.
[7]Pandit B,Halasi M,Gartel AL.p53 negatively regulates expression of FoxM1[J].Cell Cycle (Georgetown,Tex),2009,8(20):3425-3427.
[8]Barsotti AM,Prives C.Pro-proliferative FoxM1 is a target of p53-mediated repression[J].Oncogene,2009,28(48):4295-4305.
[9]Gentles AJ,Newman AM,Liu CL,et al.The prognostic landscape of genes and infiltrating immune cells across human cancers[J].Nature Medicine,2015,21(8):938-945.
[10]Falini B,Mecucci C,Tiacci E,et al.Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype[J].The New England Journal of Medicine,2005,352(3):254-266.
[11]Quentmeier H,Martelli MP,Dirks WG,et al.Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin[J].Leukemia,2005,19(10):1760-1767.
[12]Khan I,Halasi M,Zia MF,et al.Nuclear FOXM1 drives chemoresistance in AML[J].Leukemia,2017,31(1):251-255.
[13]Ganguly R,Hong CS,Smith LG,et al.Maternal embryonic leucine zipper kinase:key kinase for stem cell phenotype in glioma and other cancers[J].Mol Cancer Therapeutics,2014,13(6):1393-1398.
[14]Joshi K,Banasavadi-Siddegowda Y,Mo X,et al.MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells[J].Stem Cells,2013,31(6):1051-1063.
[15]Radhakrishnan SK,Bhat UG,Hughes DE,et al.Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1[J].Cancer Res,2006,66(19):9731-9735.
[16]Bhat UG,Halasi M,Gartel AL.FoxM1 is a general target for proteasome inhibitors[J].PloS One,2009,4(8):e6593.
[17]Kruiswijk F,Hasenfuss SC,Sivapatham R,et al.Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling[J].Oncogene,2016,35(17):2166-2177.
[18]Maachani UB,Shankavaram U,Kramp T,et al.FOXM1 and STAT3 interaction confers radioresistance in glioblastoma cells[J].Oncotarget,2016,7(47):77365-77377.
[19]Jin B,Wang C,Li J,et al.Anthelmintic niclosamide disrupts the interplay of p65 and FOXM1/beta-catenin and eradicates leukemia stem cells in chronic myelogenous leukemia[J].Clin Cancer Res,2017,23(3):789-803.
[20]Gaponenko V,Arbiser JL,Gartel AL,et al.Anthelmintic niclosamide disrupts the interplay of p65 and FOXM1/beta-catenin and eradicates leukemia stem cells in chronic myelogenous leukemia[J].Cell Death Dis,2017,23(3):789-803.
[21]Chen Y,Li Y,Xue J,et al.Wnt-induced deubiquitination FoxM1 ensures nucleus beta-catenin transactivation[J].Embo J,2016,35(6):668-684.
[22]Xu MD,Wang Y,Weng W,et al.A positive feedback loop of lncRNA-PVT1 and FOXM1 facilitates gastric cancer growth and invasion[J].Clin Cancer Res,2017,23(8):2071-2080.
[23]Clevers H.Wnt/beta-catenin signaling in development and disease[J].Cell,2006,127(3):469-480.
[24]Ma S,Tang KH,Chan YP,et al.miR-130b promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1[J].Cell Stem Cell,2010,7(6):694-707.
[25]Zhang N,Wei P,Gong A,et al.FoxM1 promotes beta-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis[J].Cancer Cell,2011,20(4):427-442.
[26]Xue J,Lin X,Chiu WT,et al.Sustained activation of SMAD3/SMAD4 by FOXM1 promotes TGF-beta-dependent cancer metastasis[J].J Clin Invest,2014,124(2):564-579.
[27]Sundqvist A,Ten Dijke P,van Dam H.Key signaling nodes in mammary gland development and cancer:Smad signal integration in epithelial cell plasticity[J].Breast Cancer Res,2012,14(1):204.
[28]Pan Y,Li J,Zhang Y,et al.Slug-upregulated miR-221 promotes breast cancer progression through suppressing E-cadherin expression[J].Sci Reports,2016,6:25798.
[29] Chan DW,Hui WW,Wang JJ,et al.DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-beta/SMAD4 signaling[J].Oncogene,2017,36(10):1404-1416.
[30]Aytes A,Mitrofanova A,Lefebvre C,et al.Cross-species regulatory network analysis identifies a synergistic interaction between FOXM1 and CENPF that drives prostate cancer malignancy[J].Cancer Cell,2014,25(5):638-651.
[31]Xu M,Qin J,Tsai SY,et al.The role of the orphan nuclear receptor COUP-TFII in tumorigenesis[J].Acta Pharmacologica Sinica,2015,36(1):32-36.
[32]Lin SC,Kao CY,Lee HJ,et al.Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer[J].Nat Commun,2016,7:11418.
[33]Halasi M,Gartel AL.A novel mode of FoxM1 regulation:positive auto-regulatory loop[J].Cell Cycle (Georgetown,Tex),2009,8(12):1966-1967.
[34]Halasi M,Varaljai R,Benevolenskaya E,et al.A novel function of molecular chaperone HSP70:Suppression of oncogenic FOXM1 after proteotoxic stress[J].J Biol Chem,2016,291(1):142-148.
[35]Zhang X,Zhang L,Du Y,et al.A novel FOXM1 isoform,FOXM1D,promotes epithelial-mesenchymal transition and metastasis through ROCKs activation in colorectal cancer[J].Oncogene,2017,36(6):807-819.